Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia

Circulation

Volumn 123, Issue 19, 2011, Pages 2120-2131

  Luong, Christina ^a   Rey Perra, Juliana ^a   Vadivel, Arul ^a   Gilmour, Greg ^b   Sauve, Yves ^b   Koonen, Debby ^a   Walker, Don ^d   Todd, Kathryn G ^b   Gressens, Pierre ^e   Kassiri, Zamaneh ^a   Nadeem, Khurram ^c   Morgan, Beverly ^a   Eaton, Farah ^a   Dyck, Jason R ^a   Archer, Stephen L ^f   Thébaud, Bernard ^a,b,c  

^a Cardiovascular Research Group   (Canada)

^b Department of Physiology ^*  (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

angiogenesis; congenital diaphragmatic hernia; pulmonary circulation; pulmonary disease

Indexed keywords

CYCLIC GMP; NITRIC OXIDE SYNTHASE; NITROFEN; PHOSPHODIESTERASE V; SILDENAFIL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; BODY WEIGHT; CONGENITAL DIAPHRAGM HERNIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; FETUS LUNG; HEART MUSCLE RELAXATION; HEART RIGHT VENTRICLE HYPERTROPHY; INCIDENCE; LUNG BLOOD VESSEL; LUNG HYPOPLASIA; LUNG STRUCTURE; NEWBORN; NONHUMAN; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

ANIMALS; BODY WEIGHT; BRAIN; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; FEMALE; HERNIA, DIAPHRAGMATIC; HYPERTENSION, PULMONARY; LUNG; NITRIC OXIDE; PHENYL ETHERS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PREGNANCY; PULMONARY ARTERY; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 79957519617     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.845909     Document Type: Article

References (60)

1. Harrison MR Keller RL Hawgood SB Kitterman JA Sandberg PL Farmer DL Lee H Filly RA Farrell JA Albanese CT. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. N Engl J Med. 2003;349:1916-1924.
2. Langham MR Jr Kays DW Ledbetter DJ Frentzen B Sanford LL Richards DS. Congenital diaphragmatic hernia: epidemiology and outcome. Clin Perinatol. 1996;23:671-688.
3. Puri P Wester T. Historical aspects of congenital diaphragmatic hernia. Pediatr Surg Int. 1997;12:95-100.
4. Bohn D. Congenital diaphragmatic hernia. Am J Respir Crit Care Med. 2002;166:911-915.
5. Thébaud B Mercier JC Dinh-Xuan AT. Congenital diaphragmatic hernia: a cause of persistent pulmonary hypertension of the newborn which lacks an effective therapy. Biol Neonate. 1998;74:323-336.
6. Bohn D Tamura M Perrin D Barker G Rabinovitch M. Ventilatory predictors of pulmonary hypoplasia in congenital diaphragmatic hernia confirmed by morphologic assessment. J Pediatr. 1987;111: 423-431.
7. Geggel RL Murphy JD Langleben D Crone RK Vacanti JP Reid LM. Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair. J Pediatr. 1985;107: 457-464.
8. Kitagawa M Hislop A Boyden EA Reid L. Lung hypoplasia in congenital diaphragmatic hernia. A quantitative study of airway artery and alveolar development. Br J Surg. 1971;58:342-346.
9. Naeye RL Shochat SJ Whitman V Maisels MJ. Unsuspected pulmonary vascular abnormalities associated with diaphragmatic hernia. Pediatrics. 1976;58:902-906.
10. Reickert CA Hirschl RB Atkinson JB Dudell G Georgeson K Glick P Greenspan J Kays D Klein M Lally KP Mahaffey S Ryckman F Sawin R Short BL Stolar CJ Thompson A Wilson JM. Congenital diaphragmatic hernia survival and use of extracorporeal life support at selected level III nurseries with multimodality support. Surgery. 1998; 123:305-310.
11. Wenstrom KD Weiner CP Hanson JW. A five-year statewide experience with congenital diaphragmatic hernia. Am J Obstet Gynecol. 1991;165: 838-842.
12. Muratore CS Kharasch V Lund DP Sheils C Friedman S Brown C Utter S Jaksic T Wilson JM. Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic. J Pediatr Surg. 2001;36:133-140.
13. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336:597-604.
14. Finer NN Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2006:CD000399.
15. Keller RL Moore P Teitel D Hawgood S McQuitty J Fineman JR. Abnormal vascular tone in infants and children with lung hypoplasia: findings from cardiac catheterization and the response to chronic therapy. Pediatr Crit Care Med. 2006;7:589-594.
16. Kinsella JP Ivy DD Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: acute late and chronic pulmonary hypertension. Semin Perinatol. 2005;29:123-128.
17. Greer JJ Babiuk RP Thébaud B. Etiology of congenital diaphragmatic hernia: the retinoid hypothesis. Pediatr Res. 2003;53:726-730.
18. Bender AT Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488-520.
19. Wharton J Strange JW Moller GM Growcott EJ Ren X Franklyn AP Phillips SC Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172:105-113.
20. Michelakis E Tymchak W Lien D Webster L Hashimoto K Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
21. Michelakis ED Tymchak W Noga M Webster L Wu XC Lien D Wang SH Modry D Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003; 108:2066-2069.
22. Thébaud B Tibboel D Rambaud C Mercier JC Bourbon JR Dinh-Xuan AT Archer SL. Vitamin A decreases the incidence and severity of nitrofen-induced congenital diaphragmatic hernia in rats. Am J Physiol. 1999;277:L423-L429.
23. Walker DK Ackland MJ James GC Muirhead GJ Rance DJ Wastall P Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse rat rabbit dog and man. Xenobiotica. 1999;29:297-310.
24. Thébaud B Michelakis E Wu XC Harry G Hashimoto K Archer SL. Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. Pediatr Res. 2002;52:19-24.
25. Thébaud B Ladha F Michelakis ED Sawicka M Thurston G Eaton F Hashimoto K Harry G Haromy A Korbutt G Archer SL. Vascular endothelial growth factor gene therapy increases survival promotes lung angiogenesis and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation. 2005; 112:2477-2486.
26. McMurtry MS Bonnet S Wu X Dyck JR Haromy A Hashimoto K Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830-840.
27. Rey-Parra GJ Archer SL Bland RD Albertine KH Carlton DP Cho SC Kirby B Haromy A Eaton F Wu X Thébaud B. Blunted hypoxic pulmonary vasoconstriction in experimental neonatal chronic lung disease. Am J Respir Crit Care Med. 2008;178:399-406.
28. Pinilla I Lund RD Sauve Y. Contribution of rod and cone pathways to the dark-adapted electroretinogram (ERG) b-wave following retinal degeneration in RCS rats. Vision Res. 2004;44:2467-2474.
29. Stege G Fenton A Jaffray B. Nihilism in the 1990s: the true mortality of congenital diaphragmatic hernia. Pediatrics. 2003;112:532-535.
30. Harrison MR Adzick NS Flake AW Jennings RW Estes JM MacGillivray TE Chueh JT Goldberg JD Filly RA Goldstein RB. Correction of congenital diaphragmatic hernia in utero: VI. Hard-earned lessons. J Pediatr Surg. 1993;28:1411-1417; discussion 1417-1418.
31. Liggins GC Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50:515-525.
32. Wilcox DT Irish MS Holm BA Glick PL. Animal models in congenital diaphragmatic hernia. Clin Perinatol. 1996;23:813-822.
33. Manson JM. Mechanism of nitrofen teratogenesis. Environ Health Perspect. 1986;70:137-147.
34. Zeman FJ Heng H Hoogenboom ER Kavlock RJ Mahboob S. Cell number and size in selected organs of fetuses of rats malnourished and exposed to nitrofen. Teratog Carcinog Mutagen. 1986;6:339-347.
35. Brown TJ Manson JM. Further characterization of the distribution and metabolism of nitrofen in the pregnant rat. Teratology. 1986;34: 129-139.
36. Muehlethaler V Kunig AM Seedorf G Balasubramaniam V Abman SH. Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants. Am J Physiol Lung Cell Mol Physiol. 2008;294: L110-L120.
37. Stenmark KR Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol. 2005;67:623-661.
38. Liebow AA. Pulmonary emphysema with special reference to vascular changes. Am Rev Respir Dis. 1959;80:67-93.
39. Jakkula M Le Cras TD Gebb S Hirth KP Tuder RM Voelkel NF Abman SH. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279: L600-L607.
40. Kasahara Y Tuder RM Taraseviciene-Stewart L Le Cras TD Abman S Hirth PK Waltenberger J Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106: 1311-1319.
41. Kunig AM Balasubramaniam V Markham NE Morgan D Montgomery G Grover TR Abman SH. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2005;289:L529-L535.
42. Ladha F Bonnet S Eaton F Hashimoto K Korbutt G Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med. 2005;172: 750-756.
43. Hara A Chapin CJ Ertsey R Kitterman JA. Changes in fetal lung distension alter expression of vascular endothelial growth factor and its isoforms in developing rat lung. Pediatr Res. 2005;58:30-37.
44. North AJ Moya FR Mysore MR Thomas VL Wells LB Wu LC Shaul PW. Pulmonary endothelial nitric oxide synthase gene expression is decreased in a rat model of congenital diaphragmatic hernia. Am J Respir Cell Mol Biol. 1995;13:676-682.
45. Shinkai T Shima H Solari V Puri P. Expression of vasoactive mediators during mechanical ventilation in nitrofen-induced diaphragmatic hernia in rats. Pediatr Surg Int. 2005;21:143-147.
46. Shinkai M Shinkai T Montedonico S Puri P. Effect of VEGF on the branching morphogenesis of normal and nitrofen-induced hypoplastic fetal rat lung explants. J Pediatr Surg. 2006;41:781-786.
47. Shinkai M Shinkai T Pirker ME Montedonico S Puri P. Effect of nitric oxide on the development of nitrofen-induced fetal hypoplastic lung explants. J Pediatr Surg. 2005;40:17-21.
48. Kluth D Buhrer Nestoris S Tander B Werner C Lambrecht W. Inhaled nitric oxide increases survival rates in newborn rats with congenital diaphragmatic hernia. Eur J Pediatr Surg. 1997;7:90-92.
49. Mann O Huppertz C Langwieler TE Tander B Bloechle C Izbicki JR Lambrecht W Kluth D. Effect of prenatal glucocorticoids and postnatal nitric oxide inhalation on survival of newborn rats with nitrofen-induced congenital diaphragmatic hernia. J Pediatr Surg. 2002;37:730-734.
50. Cloutier M Maltais F Piedboeuf B. Increased distension stimulates distal capillary growth as well as expression of specific angiogenesis genes in fetal mouse lungs. Exp Lung Res. 2008;34:101-113.
51. Gu JW Brady AL Anand V Moore MC Kelly WC Adair TH. Adenosine upregulates VEGF expression in cultured myocardial vascular smooth muscle cells. Am J Physiol. 1999;277:H595-H602.
52. Zhao X Lu X Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol. 2002;283:H2371-H2378.
53. Vidavalur R Penumathsa SV Zhan L Thirunavukkarasu M Maulik N. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin hemeoxygenase and vascular endothelial growth factor. Vascul Pharmacol. 2006;45:91-95.
54. Abbott D Comby P Charuel C Graepel P Hanton G Leblanc B Lodola A Longeart L Paulus G Peters C Stadler J. Preclinical safety profile of sildenafil. Int J Impot Res. 2004;16:498-504.
55. O'Toole SJ Irish MS Holm BA Glick PL. Pulmonary vascular abnormalities in congenital diaphragmatic hernia. Clin Perinatol. 1996;23: 781-794.
56. Karamanoukian HL Glick PL Wilcox DT O'Toole SJ Rossman JE Azizkhan RG. Pathophysiology of congenital diaphragmatic hernia. Xi: Anatomic and biochemical characterization of the heart in the fetal lamb CDH model. J Pediatr Surg. 1995;30:925-928; discussion 929.
57. Vogel M McElhinney DB Marcus E Morash D Jennings RW Tworetzky W. Significance and outcome of left heart hypoplasia in fetal congenital diaphragmatic hernia. Ultrasound Obstet Gynecol. 2010;35:310-317.
58. Jaillard S Larrue B Deruelle P Delelis A Rakza T Butrous G Storme L. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb. Ann Thorac Surg. 2006;81:935-942.
59. Larrue B Jaillard S Lorthioir M Roubliova X Butrous G Rakza T Warembourg H Storme L. Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2005;288:L1193-L1200.
60. Fraunfelder FW Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina. 2008;28:606-609.